Nal-IRI+5-FU/LV vs 5-FU/LV in metastatic pancreatic cancer - Additional safety report of randomized Japanese phase 2 trial-MedSci.cn

Nal-IRI+5-FU/LV vs 5-FU/LV in metastatic pancreatic cancer - Additional safety report of randomized Japanese phase 2 trial

Ikeda, M; Ioka, T; Ueno, M; Okusaka, T; Teng, Z; Furuya, M; Furuse, J

ANNALS OF ONCOLOGY, 2022; 33 (): S482

科室
- - 订阅+
  - 更多科室
工具
服务